ICU Medical, Inc. (ICUI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

171.19

+1.74

(+1.03%)

At close: 04:00PM EDT

171.19

0.00

(0.00%)

After hours:

04:13PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	169.45
Open	169.54
Bid	171.05 x 1300
Ask	272.99 x 800
Day's Range	169.35 - 171.65
52 Week Range	158.60 - 282.00
Volume	131,733
Avg. Volume	196,075

Market Cap	4.091B
Beta (5Y Monthly)	0.55
PE Ratio (TTM)	398.12
EPS (TTM)	0.43
Earnings Date	Nov 01, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	215.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ICUI

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

ICU Medical, Inc.
Analyst Report: ICU Medical, Inc.ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU’s acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically.
Rating
Fair Value
Economic Moat
4 days agoMorningstar

All

Benzinga
Smiths Acquisition Weighs On ICU Medical's Profitability, Shares Fall
ICU Medical Inc (NASDAQ: ICUI) reported Q2 sales of $561 million, up 75% Y/Y, due to Smiths Medical's acquisition, and missing the consensus of $566.47 million. Adjusted EPS fell from $1.88 to $1.37, missing the consensus of $1.86. Guidance: ICU Medical forecasts FY22 adjusted EBITDA of $350-$370 million, down from a prior range of $450-$500 million, and adjusted EPS of $6.20 - $6.80, compared to $9.00 - $10.50 expected earlier. Raymond James writes that while legacy ICUI continues to perform we
Zacks
ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Silvercorp (SVM) Q1 Earnings and Revenues Top Estimates
  Zacks
- National Vision (EYE) Q2 Earnings and Revenues Surpass Estimates
  Zacks
GlobeNewswire
ICU Medical Announces Second Quarter 2022 Results
Company Updated FY 2022 GuidanceSAN CLEMENTE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Results Second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year. GAAP gross profit for the second quarter of 2022 was $167.6 million, as compared to $123.5 mi